8-K
0001850902false00018509022023-08-102023-08-10

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 2054

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 10, 2023

 

ALPHA TEKNOVA, INC.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

 

Delaware

001-40538

94-3368109

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2451 Bert Drive

Hollister, CA 95023

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (831) 637-1100

N/A

(Former name, or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.00001 per share

TKNO

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


 

Item 2.02. Results of Operations and Financial Condition.

On August 10, 2023, Alpha Teknova, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2023 (the “Press Release”). A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the Press Release, is intended to be furnished under Item 2.02 and Item 9.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

 

Description

99.1

 

Press Release issued by Alpha Teknova, Inc., dated August 10, 2023

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

ALPHA TEKNOVA, INC.

Date: August 10, 2023

By:

/s/ Stephen Gunstream

 

 

Stephen Gunstream

 

 

President and Chief Executive Officer

 

 


EX-99.1

Exhibit 99.1

 

https://cdn.kscope.io/ebbebfda24c4718784259e21cd3ba5f4-img201297901_0.jpg 

 

Teknova Reports Second Quarter 2023 Financial Results

 

Second quarter 2023 total revenue was $11.5 million, up 26% sequentially

Received certification of new state-of-the-art facility for production of GMP-grade products

Company revises 2023 revenue guidance to $37-40 million, continues to anticipate free cash outflows of $30 million for full year

 

 

HOLLISTER, Calif., August 10, 2023 – Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2023.

 

“Today we reported strong operating results for the second quarter of 2023, increasing revenue sequentially by 26%, despite a challenging market environment,” said Stephen Gunstream, President and Chief Executive Officer of Teknova. “We continue to deliver to our growth strategy, with the recent certification of our new state-of-the-art facility to produce GMP-grade products that will enable us to expand our revenue capacity to $200 million. Due to near-term headwinds persisting in bioprocessing, however, we are reducing our 2023 revenue outlook. We nonetheless remain optimistic about the long-term potential of our target markets.”

“During the first half of 2023, we managed our overall expenses and capital expenditures to plan. Despite the lower revenue outlook, we continue to expect full-year free cash outflow to remain at approximately $30 million,” explained Matt Lowell, Teknova’s Chief Financial Officer.

 

Corporate and Financial Updates

 

Earned second quarter 2023 total revenue of $11.5 million, up 26% from the first quarter 2023 and slightly lower compared to the second quarter 2022
Received certification of our new state-of-the-art manufacturing facility for the production of GMP-grade products
Expanded our proprietary product line, AAV-Tek Solutions, by introducing an additional version of our first-of-its-kind AEX Buffer Screening Kit for the AAV8 serotype, as well as 24 new catalog reagents, to deliver end-to-end solutions for gene therapy process development
Teknova and Sartorius BIA Separations demonstrated a reliable and scalable approach for the enhancement of AAV full capsid enrichment with an optimized AEX Platform
Ended the second quarter 2023 with a cash position of $23.7 million and gross debt of $22.1 million

1

 


Certain fixed assets were impaired, resulting in a non-recurring, non-cash impairment charge of $2.2 million in the second quarter 2023

 

Revenue for the Second Quarter and Year-to-Date

 

 

 

For the Three Months Ended June 30,

 

 

For the Six Months Ended June 30,

 

(Dollars in thousands)

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Lab Essentials

 

$

7,581

 

 

$

8,393

 

 

$

14,838

 

 

$

15,368

 

Clinical Solutions

 

 

3,653

 

 

 

2,943

 

 

 

5,262

 

 

 

6,755

 

Other

 

 

293

 

 

 

354

 

 

 

548

 

 

 

714

 

Total revenue

 

$

11,527

 

 

$

11,690

 

 

$

20,648

 

 

$

22,837

 

 

Second Quarter 2023 Financial Results

 

Total revenue for the second quarter 2023 was $11.5 million, down 1% compared to $11.7 million in the second quarter 2022. Lab Essentials revenue was $7.6 million in the second quarter 2023, down 10% compared to $8.4 million in the second quarter 2022. Clinical Solutions revenue was $3.7 million, up 24% compared to $2.9 million in the second quarter 2022.

Gross profit for the second quarter 2023 was $5.1 million, compared to $5.2 million in the second quarter 2022. Gross margin for the second quarter 2023 was 43.9%, compared to 44.9% in the second quarter 2022. Despite increased overhead costs in the second quarter 2023, including depreciation from our new manufacturing facility, our gross margins were down only slightly compared to the second quarter 2022 as higher margin Clinical Solutions revenue represented a larger percentage of our total revenue in the second quarter 2023 compared to the second quarter 2022.

Operating expenses for the second quarter 2023 were $12.1 million, compared to $11.9 million in the second quarter 2022. Excluding the non-recurring, non-cash impairment charge related to certain fixed assets of $2.2 million, operating expenses were down $2.0 million in the second quarter 2023 compared to the second quarter 2022. The decrease was driven by reduced spending, primarily in professional fees and occupancy costs.

Net loss for the second quarter 2023 was $7.2 million, or negative $0.25 per diluted share, compared to $6.2 million, or negative $0.22 per diluted share, for the second quarter 2022.

Adjusted EBITDA for the second quarter 2023 was negative $2.3 million, compared to negative $4.9 million for the second quarter 2022. Free Cash Flow was negative $6.2 million for the second quarter 2023, compared to negative $16.8 million for the second quarter 2022.

 

2023 Outlook

 

Teknova is revising its fiscal 2023 outlook for revenue but maintaining its expectation for free cash outflow. The Company now anticipates total revenue of $37 million to $40 million for the fiscal year ending December 31, 2023 (“2023”), which assumes a Lab Essentials range from down 9% to

2

 


down 5% and a Clinical Solutions range from down 15% to up 5%. The Company continues to anticipate a free cash outflow amount of approximately $30 million for 2023.

 

Upcoming Investor Conference

Sidoti Virtual Micro-Cap Conference

Thursday, August 17, 2023 at 2:30 p.m. ET

https://sidoti.zoom.us/webinar/register/WN_EfIdZfmdT-6eLFcmczHxKw

 

Conference Call and Webcast

 

Teknova will host a webcast and conference call on Thursday, August 10, 2023, beginning at 5:30 p.m. ET. Participants can access the live webcast on the Investor Relations section of the Teknova website and at this link: https://edge.media-server.com/mmc/p/uwatr9e7. To receive a PIN for dialing in, participants can register for the webcast via this link: https://register.vevent.com/register/BIb15ae1239db14699b0b6f88ed3ff392a. The webcast will be available for replay on the Company’s website approximately two hours after the event.

 

About Teknova

 

Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture media, buffers, reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.

 

Non-GAAP Financial Measures

 

This press release contains financial measures that have not been calculated in accordance with U.S. generally accepted accounting principles (GAAP). Teknova uses the following non-GAAP financial measures in assessing the performance of its business and the effectiveness of its business strategies: (a) Adjusted EBITDA and (b) Free Cash Flow.

 

Teknova defines Adjusted EBITDA as net loss adjusted for interest income (expense), net, benefit from income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that Teknova does not consider representative of its ongoing operating performance.

 

3

 


Teknova defines Free Cash Flow as cash used in operating activities less purchases of property, plant, and equipment.

 

Teknova presents Adjusted EBITDA and Free Cash Flow in this press release because Teknova believes that analysts, investors, and other interested parties frequently use these measures to evaluate companies in Teknova’s industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Teknova also believes such measures are helpful in highlighting trends in Teknova’s operating results because they exclude items that are not indicative of Teknova’s core operating performance. Investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by Teknova may be different from the non-GAAP financial measures used by other companies.

 

A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.

 

Forward-Looking Statements

 

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to Teknova’s anticipated total revenue, including our expectations for 2023 revenue guidance, expected growth in Lab Essentials and Clinical Solutions, ongoing capacity expansion, new research and development products, prospects, including to achieve profitability, strategy of managing operating expenses, and long-term growth strategy. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond Teknova’s control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, demand for Teknova’s products (including the potential delay or pausing of customer orders); Teknova’s assessment of fundamental indicators of future demand across its target customer base; Teknova’s ability to expand its production, commercial, and research and development capabilities; Teknova’s cash flows and revenue growth rate; Teknova’s supply chain, sourcing, manufacturing and warehousing; inventory management; risks related to global economic and marketplace uncertainties, including those related to the impact of the COVID-19 pandemic; reliance on a limited number of customers for a high percentage of Teknova’s revenue; potential acquisitions and integration of other companies; and other factors discussed in the “Risk Factors” section of Teknova’s most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including in Teknova’s Annual Report on Form 10-K for the year ended December 31, 2022, and subsequent Quarterly Reports on Form 10-Q filed with the SEC, all of which you may obtain for free on the SEC’s website at www.sec.gov.

4

 


Although Teknova believes that the expectations reflected in its forward-looking statements are reasonable, Teknova does not know whether its expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by Teknova on its website or otherwise. Teknova does not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

 

Investor Contacts Media Contact

Matt Lowell Jennifer Henry

Chief Financial Officer Senior Vice President, Marketing

matt.lowell@teknova.com jenn.henry@teknova.com

+1 831-637-1100 +1 831-313-1259

Sara Michelmore

MacDougall Advisors

smichelmore@macdougall.bio

+1 781-235-3060

 

 

5

 


ALPHA TEKNOVA, INC.

Condensed Statements of Operations

(Unaudited)

(In thousands, except share and per share data)

 

 

 

For the Three Months Ended June 30,

 

 

For the Six Months Ended June 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Revenue

 

$

11,527

 

 

$

11,690

 

 

$

20,648

 

 

$

22,837

 

Cost of sales

 

 

6,461

 

 

 

6,443

 

 

 

13,159

 

 

 

12,241

 

Gross profit

 

 

5,066

 

 

 

5,247

 

 

 

7,489

 

 

 

10,596

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

1,464

 

 

 

1,929

 

 

 

2,859

 

 

 

3,942

 

Sales and marketing

 

 

2,174

 

 

 

2,598

 

 

 

4,517

 

 

 

4,195

 

General and administrative

 

 

5,943

 

 

 

7,059

 

 

 

13,288

 

 

 

14,354

 

Amortization of intangible assets

 

 

287

 

 

 

287

 

 

 

573

 

 

 

574

 

Long-lived assets impairment

 

 

2,195

 

 

 

 

 

 

2,195

 

 

 

 

Total operating expenses

 

 

12,063

 

 

 

11,873

 

 

 

23,432

 

 

 

23,065

 

Loss from operations

 

 

(6,997

)

 

 

(6,626

)

 

 

(15,943

)

 

 

(12,469

)

Other (expenses) income, net

 

 

 

 

 

 

 

 

 

 

 

 

Interest (expense) income, net

 

 

(308

)

 

 

28

 

 

 

(215

)

 

 

15

 

Other income, net

 

 

166

 

 

 

 

 

 

184

 

 

 

 

Total other (expenses) income, net

 

 

(142

)

 

 

28

 

 

 

(31

)

 

 

15

 

Loss before income taxes

 

 

(7,139

)

 

 

(6,598

)

 

 

(15,974

)

 

 

(12,454

)

Provision for (benefit from) income taxes

 

 

15

 

 

 

(395

)

 

 

(3

)

 

 

(754

)

Net loss

 

$

(7,154

)

 

$

(6,203

)

 

$

(15,971

)

 

$

(11,700

)

Net loss per share—basic and diluted

 

$

(0.25

)

 

$

(0.22

)

 

$

(0.57

)

 

$

(0.42

)

Weighted average shares used in computing net loss per share—basic and diluted

 

 

28,272,306

 

 

 

28,057,801

 

 

 

28,227,132

 

 

 

28,044,460

 

 

 

6

 


ALPHA TEKNOVA, INC.

Condensed Balance Sheets

(Unaudited)

(In thousands)

 

 

 

As of June 30,

 

 

As of December 31,

 

 

 

2023

 

 

2022

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

23,710

 

 

$

42,236

 

Accounts receivable, net

 

 

4,572

 

 

 

4,261

 

Contract assets

 

 

1,050

 

 

 

 

Inventories, net

 

 

12,018

 

 

 

12,247

 

Income taxes receivable

 

 

22

 

 

 

22

 

Prepaid expenses and other current assets

 

 

1,741

 

 

 

2,374

 

Total current assets

 

 

43,113

 

 

 

61,140

 

Property, plant, and equipment, net

 

 

52,861

 

 

 

51,577

 

Operating right-of-use lease assets

 

 

17,561

 

 

 

19,736

 

Intangible assets, net

 

 

16,983

 

 

 

17,556

 

Other non-current assets

 

 

2,030

 

 

 

2,252

 

Total assets

 

$

132,548

 

 

$

152,261

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

1,081

 

 

$

2,449

 

Accrued liabilities

 

 

3,658

 

 

 

6,203

 

Current portion of operating lease liabilities

 

 

1,751

 

 

 

2,223

 

Current debt, net

 

 

22,162

 

 

 

 

Total current liabilities

 

 

28,652

 

 

 

10,875

 

Deferred tax liabilities

 

 

1,219

 

 

 

1,223

 

Other accrued liabilities

 

 

147

 

 

 

191

 

Long-term debt, net

 

 

 

 

 

21,976

 

Long-term operating lease liabilities

 

 

16,322

 

 

 

18,111

 

Total liabilities

 

 

46,340

 

 

 

52,376

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock

 

 

 

 

 

 

Common stock

 

 

 

 

 

 

Additional paid-in capital

 

 

157,185

 

 

 

154,891

 

Accumulated deficit

 

 

(70,977

)

 

 

(55,006

)

Total stockholders’ equity

 

 

86,208

 

 

 

99,885

 

Total liabilities and stockholders’ equity

 

$

132,548

 

 

$

152,261

 

 

 

7

 


ALPHA TEKNOVA, INC.

Condensed Statements of Cash Flows

(Unaudited)

(In thousands)

 

 

 

For the Three Months Ended June 30,

 

 

For the Six Months Ended June 30,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(7,154

)

 

$

(6,203

)

 

$

(15,971

)

 

$

(11,700

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Bad debt expense

 

 

6

 

 

 

25

 

 

 

8

 

 

 

32

 

Inventory reserve

 

 

177

 

 

 

(4

)

 

 

33

 

 

 

(8

)

Depreciation and amortization

 

 

1,297

 

 

 

792

 

 

 

2,427

 

 

 

1,543

 

Stock-based compensation

 

 

1,070

 

 

 

934

 

 

 

2,080

 

 

 

1,721

 

Deferred taxes

 

 

15

 

 

 

(391

)

 

 

(4

)

 

 

(751

)

Amortization of debt financing costs

 

 

120

 

 

 

53

 

 

 

210

 

 

 

99

 

Non-cash lease expense

 

 

(16

)

 

 

75

 

 

 

31

 

 

 

181

 

Long-lived assets impairment

 

 

2,195

 

 

 

 

 

 

2,195

 

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

  Accounts receivable

 

 

199

 

 

 

143

 

 

 

(319

)

 

 

(1,176

)

  Contract assets

 

 

(1,050

)

 

 

 

 

 

(1,050

)

 

 

 

  Inventories

 

 

(44

)

 

 

(1,479

)

 

 

196

 

 

 

(2,507

)

  Income taxes receivable

 

 

 

 

 

1,071

 

 

 

 

 

 

1,071

 

  Prepaid expenses and other current assets

 

 

771

 

 

 

190

 

 

 

1,042

 

 

 

737

 

  Other non-current assets

 

 

120

 

 

 

(373

)

 

 

222

 

 

 

(589

)

  Accounts payable

 

 

(976

)

 

 

(515

)

 

 

(1,362

)

 

 

(278

)

  Accrued liabilities

 

 

(564

)

 

 

(136

)

 

 

(1,234

)

 

 

626

 

  Other

 

 

(22

)

 

 

(20

)

 

 

(44

)

 

 

(40

)

    Cash used in operating activities

 

 

(3,856

)

 

 

(5,838

)

 

 

(11,540

)

 

 

(11,039

)

Investing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Purchase of property, plant, and equipment

 

 

(2,338

)

 

 

(10,920

)

 

 

(6,650

)

 

 

(16,837

)

    Cash used in investing activities

 

 

(2,338

)

 

 

(10,920

)

 

 

(6,650

)

 

 

(16,837

)

Financing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Proceeds from long-term debt

 

 

 

 

 

5,135

 

 

 

 

 

 

5,135

 

Payment of debt issuance costs

 

 

(24

)

 

 

(151

)

 

 

(24

)

 

 

(151

)

Payment of exit fee costs

 

 

 

 

 

(135

)

 

 

 

 

 

(135

)

Payment of offering costs

 

 

(361

)

 

 

 

 

 

(395

)

 

 

 

Proceeds from exercise of stock options

 

 

67

 

 

 

44

 

 

 

76

 

 

 

99

 

Proceeds from issuance of common stock under employee stock purchase plan

 

 

138

 

 

 

144

 

 

 

138

 

 

 

144

 

    Cash (used in) provided by financing activities

 

 

(180

)

 

 

5,037

 

 

 

(205

)

 

 

5,092

 

Change in cash, cash equivalents, and restricted cash

 

 

(6,374

)

 

 

(11,721

)

 

 

(18,395

)

 

 

(22,784

)

Cash, cash equivalents, and restricted cash at beginning of period

 

 

30,215

 

 

 

76,455

 

 

 

42,236

 

 

 

87,518

 

Cash, cash equivalents, and restricted cash at end of period

 

$

23,841

 

 

$

64,734

 

 

$

23,841

 

 

$

64,734

 

 

 

8

 


ALPHA TEKNOVA, INC.

Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures

(Unaudited)

(In thousands)

 

 

 

For the Three Months Ended June 30,

 

 

For the Six Months Ended June 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Net loss – as reported

 

$

(7,154

)

 

$

(6,203

)

 

$

(15,971

)

 

$

(11,700

)

Add back:

 

 

 

 

 

 

 

 

 

 

 

 

Interest (expense) income, net

 

 

(308

)

 

 

28

 

 

 

(215

)

 

 

15

 

Provision for (benefit from) income taxes

 

 

15

 

 

 

(395

)

 

 

(3

)

 

 

(754

)

Depreciation expense

 

 

1,010

 

 

 

505

 

 

 

1,854

 

 

 

969

 

Amortization of intangible assets

 

 

287

 

 

 

287

 

 

 

573

 

 

 

574

 

EBITDA

 

$

(5,534

)

 

$

(5,834

)

 

$

(13,332

)

 

$

(10,926

)

Other and non-recurring expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

1,070

 

 

 

934

 

 

 

2,080

 

 

 

1,721

 

Severance pay and other termination benefits

 

 

 

 

 

 

 

 

725

 

 

 

 

Long-lived assets impairment

 

 

2,195

 

 

 

 

 

 

2,195

 

 

 

 

Adjusted EBITDA

 

$

(2,269

)

 

$

(4,900

)

 

$

(8,332

)

 

$

(9,205

)

 

 

 

For the Three Months Ended June 30,

 

 

For the Six Months Ended June 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Cash used in operating activities

 

$

(3,856

)

 

$

(5,838

)

 

$

(11,540

)

 

$

(11,039

)

Purchase of property, plant, and equipment

 

 

(2,338

)

 

 

(10,920

)

 

 

(6,650

)

 

 

(16,837

)

Free Cash Flow

 

$

(6,194

)

 

$

(16,758

)

 

$

(18,190

)

 

$

(27,876

)

 

9